Clinical Trial Corner

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

Researchers are enrolling patients in a trial of ELI-00 7P — a vaccine to treat KRAS-mutant cancer.

Patients with advanced gynecologic cancer given IMNN-001 with presurgical chemotherapy tended to live nearly a year longer.

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care.

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma.

Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with advanced solid tumors.

A new arm of a clinical trial will investigate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer.

A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

The novel drug, IDP-023, is being investigated in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma.

A phase 2 trial is evaluating ELI-002 7P, a novel cancer vaccine, for the treatment of patients with KRAS-mutant pancreatic cancer.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

B42-001, a novel CAR-T cell therapy, will be tested in a phase 1 trial for the treatment of patients with BT-001—positive solid cancers.

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas.

A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma.

An ongoing phase 1 trial is analyzing the use of a novel cancer vaccine plus the immunotherapy agent, Keytruda, for patients with triple-negative breast cancer.